Application of quantitative pharmacology in development of therapeutic monoclonal antibodies.

The AAPS Journal
Mohammad A TabriziHamza Suria

Abstract

The advancement of therapeutic monoclonal antibodies during various stages of the drug development process can be effectively streamlined when appropriate translational strategies are applied. Design of successful translational strategies for development of monoclonal antibodies should allow for understanding of the dose- and concentration-response relationships with respect to both beneficial and toxic effects from early phases of drug development. Evaluation of relevant biomarkers during early stages of drug development should facilitate the successful design of safe and effective dosing strategies. Moreover, application of quantitative pharmacology is critical for translation of exposure-response relationships early on.

References

Oct 1, 1986·The Journal of Allergy and Clinical Immunology·G Levy
Jan 1, 1972·Annual Review of Pharmacology·G Levy, M Gibaldi
Jan 1, 1982·Pharmacology & Therapeutics·N H Holford, L B Sheiner
Sep 1, 1994·Clinical Pharmacology and Therapeutics·G Levy
Oct 1, 1994·Clinical Pharmacology and Therapeutics·W J Jusko, H C Ko
Aug 15, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P McLaughlinB K Dallaire
Dec 23, 1999·The New England Journal of Medicine·H MilgromW J Metzger
Feb 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M S GordonD Adelman
May 10, 2002·Journal of Pharmacokinetics and Pharmacodynamics·D E Mager, W J Jusko
Dec 3, 2002·Pharmaceutical Research·Vanessa HseiJacques Gaudreault
Feb 14, 2003·The New England Journal of Medicine·Filip BaertPaul Rutgeerts
Mar 26, 2003·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Yulia VugmeysterEleanor Canova-Davis
Apr 16, 2003·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Donald E MagerWilliam J Jusko
Aug 30, 2003·International Immunopharmacology·Yulia VugmeysterEleanor Canova-Davis
Feb 18, 2004·International Journal of Radiation Oncology, Biology, Physics·Kenneth A FoonGisela M Schwab
Feb 26, 2004·Paediatric Respiratory Reviews·Leslie HendelesSarah Chesrown
Apr 28, 2004·Trends in Biotechnology·Peter KuferPatrick A Baeuerle
Jun 24, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric K RowinskyJanice Dutcher
Sep 25, 2004·Journal of Pharmaceutical Sciences·Evelyn D LoboJoseph P Balthasar
Sep 28, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rinpei NiwaKenya Shitara
Jan 7, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Qian GongAndrew C Chan
Jan 14, 2005·The Journal of Pharmacology and Experimental Therapeutics·Jeannie R RojasCarrie L Wagner
Feb 3, 2005·International Journal of Cancer. Journal International Du Cancer·Patrick HoffmannPatrick A Baeuerle
Apr 15, 2005·Clinical Pharmacokinetics·Iftekhar Mahmood, Martin D Green
May 4, 2005·Cancer Chemotherapy and Pharmacology·Rene BrunoPamela Klein
Jun 21, 2005·Journal of Pharmaceutical and Biomedical Analysis·Dong GengCarrie Wagner
Sep 10, 2005·Nature Biotechnology·Gregory P Adams, Louis M Weiner
Feb 16, 2006·Drug Discovery Today·Mohammad A TabriziLorin K Roskos
Feb 21, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jean-Jacques BodyPirow J Bekker
Feb 24, 2006·The New England Journal of Medicine·Michael R McClungUNKNOWN AMG 162 Bone Loss Study Group
Mar 11, 2006·Current Osteoporosis Reports·Michael R McClung
Apr 20, 2006·Nature Reviews. Immunology·Paul J Carter
Jul 1, 2006·Journal of Clinical Pharmacology·Lorin K RoskosBing-Bing Yang
Aug 16, 2006·The New England Journal of Medicine·Ganesh SuntharalingamNicki Panoskaltsis
Oct 28, 2006·Annual Review of Pharmacology and Toxicology·Meindert DanhofRob A Voskuyl
Nov 14, 2006·British Journal of Clinical Pharmacology·Naoto HayashiPhilip J Lowe
Jan 11, 2007·Clinical Therapeutics·Ted Shih, Celeste Lindley
Feb 3, 2007·Nature Reviews. Drug Discovery·Kathryn ChapmanIan Ragan
Apr 4, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Saifee A MullamithaGordon C Jayson

❮ Previous
Next ❯

Citations

Jan 10, 2013·Clinical Pharmacokinetics·Miroslav DostalekManoranjenni Chetty
May 6, 2015·Expert Opinion on Drug Metabolism & Toxicology·Lei Diao, Bernd Meibohm
Mar 20, 2013·Journal of Pharmaceutical Sciences·Leijun Hu, Ryan J Hansen
Oct 15, 2014·Mathematical Biosciences·Ayse Meric Ovacik
Apr 3, 2013·Journal of the American Chemical Society·Eugene F DouglassDavid A Spiegel
Oct 4, 2016·Clinical Pharmacokinetics·Amanda LongJohan Wallin
Nov 10, 2020·Melanoma Research·Trevor S AndersonDevin B Lowe
Apr 14, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Steven CoatsJean-Charles Soria

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2021 Meta ULC. All rights reserved